The cytokeratin profile of medullary carcinoma of the breast

Histopathology

Volumn 37, Issue 2, 2000, Pages 175-181

  Tot, T ^a  

^a FALUN HOSPITAL   (Sweden)

Author keywords

Breast; Cytokeratins; Medullary carcinoma; Metastases; Vimentin

Indexed keywords

CYTOKERATIN; VIMENTIN;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA, MEDULLARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; NEOPLASM METASTASIS; PROTEIN ISOFORMS;

EID: 0033852196     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2000.00889.x     Document Type: Article

References (44)

1. Moore OS Jr, Foote FW Jr. The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 1949; 2; 635-642.
2. Rindolfi R, Rosen PP, Port A et al. Medullary carcinoma of the breast. A clinicopathologic study with 10 years follow-up. Cancer 1977; 40; 1365-1385.
3. Rosen PP. Medullary carcinoma. In: Rosen PP ed, Breast Pathology. New York, NY: Lippincott-Raven, 1997: 355-374.
4. Moll R, Franke WW, Schiller DL et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31; 11-24.
5. Bartek J, Taylor-Papadimitriou J, Miller N et al. Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int. J. Cancer 1985; 36; 299-306.
6. Guelstein VI, Tchypysheva TA, Ermilova VD et al. Monoclonal antibody mapping of keratins 8 and 17 and vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int. J. Cancer 1988; 42; 147-153.
7. Tsubura A, Okada H, Senzaki H et al. Keratin expression in the normal breast and in breast carcinoma. Histopathology 1991; 18; 517-522.
8. Ramaekers F, van Niekerk C, Poels L et al. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am. J. Pathol. 1990; 136; 641-655.
9. Purkis PE, Steel JB, Mackeanzie IC et al. Antibody markers of basal cells in complex epithelia. J. Cell Sci. 1990; 97; 39-50.
10. Böcker W, Bier B, Freytag G et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part II. epitheliosis and ductal carcinoma in situ. Virchows Arch. (a) 1992; 421; 323-330.
11. Wetzels RHW, Kuijpers HJH, Lane EB et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am. J. Pathol. 1991; 138; 751-763.
12. Jarasch E-D, Nagle RB, Kauffmann M et al. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum. Pathol. 1988; 19; 276-289.
13. Gould VE, Koukoulis GK, Jansson DS et al. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast. Am. J. Pathol. 1990; 137; 1143-1155.
14. Wetzels RHW, Holland R, van Healst UJGM et al. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am. J. Pathol. 1989; 134; 571-579.
15. Malzahn K, Mitze M, Thoenes M et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998; 433; 119-129.
16. Hiroyuki T, Iino Y, Horiguchi J et al. Low and high molecular weight cytokeratins in invasive breast carcinoma. Oncol. Rep. 1997; 4; 33-38.
17. Battifora H. Diagnostic uses of antibodies to keratins: a review and immunohistochemical comparison of seven monoclonal and three polyclonal antibodies. In: Fenoglio-Preiser CM, Wolff M, Rilke F, eds. Progress in Surgical Pathology, Vol. VIII. Berlin, Heidelberg, New York, London, Paris, Tokyo: Springer-Verlag, 1988: 1-16.
18. Leader M, Patel J, Makin C et al. An analysis of the sensitivity and specificity of the cytokeratin marker CAM5,2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology 1986; 10; 1315-1324.
19. Wang NP, Zee S, Zarbo RJ et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl. Immunohist. 1995; 3; 99-107.
20. Wauters CCAP, Smedts F, Gerrits LGM et al. Keratin 7 an 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum. Pathol. 1995; 26; 852-855.
21. Loy TS, Calaluce RD, Keeney GL. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod. Pathol. 1996; 9; 1040-1044.
22. Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum. Pathol. 1998; 29; 1393-1402.
23. Tot T. Adenocarcinomas metastatic to the liver - the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer 1999; 85; 171-7.
24. Santini D, Ceccarelli C, Taffurelli M et al. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J. Pathol. 1996; 179; 386-391.
25. van Niekerk CC, Boerman OC, Ramaekers FCS et al. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas. Am. J. Pathol. 1991; 138; 455-463.
26. Hiroyuki T, Iino Y, Horighuchi J et al. Immunohistochemical analysis of cytokeratin 8 as a prognostic factor in invasive breast carcinoma. Anticancer Res. 1995; 15; 1101-1106.
27. Raymond WA, Leong AS-Y. Vimentin - a new prognostic parameter in breast carcinoma? J. Pathol. 1989; 158; 107-114.
28. Domagala W, Lasota J, Dukowicz A et al. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am. J. Pathol. 1990; 137; 1299-1304.
29. Larsimont D, Lespagnard L, Degeyter M et al. Medullary carcinoma of the breast: a tumour lacking keratin 19. Histopathology 1994; 24; 549-552.
30. Dalal P, Shousha S. Keratin 19 in paraffin sections of medullary carcinoma and other benign and malignant breast lesions. Mod. Pathol. 1995; 8; 413-416.
31. Holck S, Pedersen L, Schiodt T et al. Vimentin expression in 98 cancers with medullary features and its prognostic significance. Virchows Arch. A 1993; 422; 475-479.
32. Seshadri R, Raymond WA, Leong AS-Y et al. Vimentin expression is not associated with poor prognosis in breast cancer. Int. J. Cancer 1996; 67; 353-356.
33. Moll R, Löwe A, Laufer J et al. Cytokeratin 20 in human carcinomas. Am. J. Pathol. 1992; 140; 427-447.
34. Tot T. Patterns of distribution of cytokeratins 20 and 7 in special types of invasive breast carcinoma: a study of 123 cases. Ann Diagn Pathol 1999; 3; 350-356.
35. Sloane JP, Amendoeira I, Apostolakis N et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. Virchows Arch. 1999; 434; 3-10.
36. Makin CA, Bobrow LG, Bodmer WF. Monoclonal antibody to cytokeratin for use in routine histopathology. J. Clin. Pathol. 1984; 37; 975-983.
37. Kwaspen FHL, Smedts FMM, Broos A et al. Reproducible and highly sensitive detection of the broad spectrum epithelial marker keratin 19 in routine cancer diagnosis. Histopathology 1997; 31; 503-516.
38. Savera AT, Torres FX, Linden MD et al. Primary versus metastatic pulmonary adenocarcinoma: an immunohistochemical study using villin, cytokeratin 7 and 20. Appl. Immunohistochem. 1996; 4; 86-94.
39. Kauffmann O, Deidesheimer T, Muehlenberg G et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary site. Histopathology 1996; 29; 233-240.
40. Ascoli V, Taccogna S, Scalzo CC. et al. Utility of cytokeratin 20 in identifying the origin of metastatic carcinomas in effusions. Diagn. Cytopathol. 1995; 12; 303-308.
41. Heatley M, Maxwell P, Whiteside C et al. Cytokeratin intermediate filament expression in benign and malignant breast disease. J. Clin. Pathol. 1995; 48; 26-32.
42. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997; 31; 140-143.
43. Ordonez GN. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am. J. Surg. Pathol. 1998; 22; 1215-1221.
44. Su L, Morgan PR, Lane EB. Expression of cytokeratin messenger RNA versus protein in the normal mammary gland and in breast cancer. Hum. Pathol. 1996; 27; 800-806.